Blockade of tumor cell-intrinsic PD-L1 signaling enhances AURKA-targeted therapy in triple negative breast cancer

Triple negative breast cancer (TNBC) accounts for 15–20% of all breast cancers and mainly affects pre-menopausal and minority women. Because of the lack of ER, PR or HER2 expression in TNBC, there are limited options for tailored therapies. While TNBCs respond initially to standard of care chemother...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Andrew Takchi, Minzhi Zhang, Mohammad Jalalirad, Roberto Leon Ferre, Royal Shrestha, Tufia Haddad, Jann Sarkaria, Ann Tuma, Jodi Carter, Hillman David, Karthik Giridhar, Liewei Wang, Carol Lange, Urban Lendahl, James Ingle, Matthew Goetz, Antonino Bonaventura D’Assoro
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-05-01
Subjects:	triple negative breast cancer immunotherapy cancer cell plasticity small molecule inhibitor organ metastases
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1384277/full